November 2023
·
59 Reads
·
1 Citation
Dermatologica Sinica
What is this page?
This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.
Publications (2)
June 2023
·
110 Reads
·
3 Citations
Ixekizumab (Taltz®) is a humanized anti-IL-17A monoclonal antibody approved for the treatment of various inflammatory diseases including psoriasis and psoriatic arthritis. Despite the favorable efficacy and safety, ixekizumab is also known for its high incidence of injection site reactions (ISRs), ranging from 6% to 55% in different studies according to different definitions and studied population. However, specific risk factors for ixekizumab-induced injection site reactions in patients with psoriatic diseases had not been well studied. In this retrospective study, we found that overweight or obesity might be a protective predictor for the occurrence of ixekizumab-induced ISRs in patients with psoriatic disease. Meanwhile, having a positive family history of psoriasis might be a potential risk factor. Last but not least, patients with diarrhea following ixekizumab injection were associated with a higher risk of developing ISRs. Future high-quality studies with larger samples are warranted to verify the relationship.
Citations (1)
... As regards possible predictive factors for ISR development, heavier body weight seems to be a protective factor, as reported in literature, probably due to differences in subcutaneous fat thickness between normal-weight and obese patients. On the contrary, having a family history of psoriasis could be a possible risk factor [105]. Of interest, patients with diarrhea following ixekizumab injection seem to be associated with a higher risk of developing ISRs [105]. ...
- Citing Article
- Full-text available
June 2023